Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ebtsam M. Abdou, Soha M. Kandil, Amany Morsi & Maysa W. Sleem. (2019) In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. Drug Delivery 26:1, pages 689-699.
Read now
Read now
Abigail L. Chua & Stephen Silberstein. (2016) Inhaled drug therapy development for the treatment of migraine. Expert Opinion on Pharmacotherapy 17:13, pages 1733-1743.
Read now
Read now
Miguel JA Láinez, Ana García-Casado & Francisco Gascón. (2013) Optimal management of severe nausea and vomiting in migraine: improving patient outcomes. Patient Related Outcome Measures 4, pages 61-73.
Read now
Read now
Martha B Ramírez Rosas, Sieneke Labruijere, Carlos M Villalón & Antoinette Maassen VanDenBrink. (2013) Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Opinion on Pharmacotherapy 14:12, pages 1599-1610.
Read now
Read now
Articles from other publishers (14)
Ahmed Alastal, Amani D. Abu Kwaik, Azzam A. Malkawi, Sarah Baltzley & Abeer M. Al-Ghananeem. (2023) Enhancing Intranasal Delivery and Bioavailability of Dihydroergotamine Utilizing Chitosan Nanoparticles. Journal of Clinical Pharmacy and Therapeutics 2023, pages 1-8.
Crossref
Crossref
Alaa Ibrahim, Omar A. Abdel Aziz, Ahmed S. Abo Dena & Ibrahim M. El-Sherbiny. 2023. Advanced and Modern Approaches for Drug Delivery. Advanced and Modern Approaches for Drug Delivery
91
111
.
Srushti J. Sodha, Manan Patel, Rigved Nagarkar, Irfan A. Mohammed & Hiren Patel. (2021) Translation of pulmonary protein therapy from bench to bedside: Addressing the bioavailability challenges. Journal of Drug Delivery Science and Technology 64, pages 102664.
Crossref
Crossref
Spingos Konstantinos, Michail Vikelis & Alan Rapoport. (2020) Acute Care and Treatment of Migraine. Journal of Neuro-Ophthalmology 40:4, pages 472-484.
Crossref
Crossref
Kevin W. Stapleton. (2018) Orally inhaled migraine therapy: Where are we now?. Advanced Drug Delivery Reviews 133, pages 131-134.
Crossref
Crossref
Angela Deneris, Peggy Rosati Allen, Emily Hart Hayes & Gwen Latendresse. (2017) Migraines in Women: Current Evidence for Management of Episodic and Chronic Migraines. Journal of Midwifery & Women's Health 62:3, pages 270-285.
Crossref
Crossref
Anne Lexmond & Ben Forbes. 2017. Pharmacology and Therapeutics of Asthma and COPD. Pharmacology and Therapeutics of Asthma and COPD
265
280
.
Richard B. Lipton & Stephen D. Silberstein. (2015) Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache: The Journal of Head and Face Pain 55, pages 103-122.
Crossref
Crossref
Sieneke Labruijere, Kayi Y Chan, René de Vries, Antoon J van den Bogaerdt, Clemens M Dirven, AH Jan Danser, Shashidhar H Kori & Antoinette MaassenVanDenBrink. (2014) Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein. Cephalalgia 35:2, pages 182-189.
Crossref
Crossref
Peer C. Tfelt-Hansen & Hans-Christoph Diener. (2014) Use of Dihydroergotamine (DHE) Should Be Restricted to No More Than Twice a Week. Headache: The Journal of Head and Face Pain 54:9, pages 1523-1525.
Crossref
Crossref
Sarah Vollbracht & Alan M. Rapoport. (2014) New treatments for headache. Neurological Sciences 35:S1, pages 89-97.
Crossref
Crossref
Peer Tfelt-Hansen. (2014) Is Orally Inhaled Dihydroergotamine (DHE) Equivalent in Efficacy in Migraine to Intravenous DHE?. Headache: The Journal of Head and Face Pain 54:2, pages 383-383.
Crossref
Crossref
Peer C Tfelt-Hansen. (2013) Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review. Cephalalgia 33:13, pages 1122-1131.
Crossref
Crossref
Sarah Vollbracht & Alan M. Rapoport. (2013) The Pipeline in Headache Therapy. CNS Drugs 27:9, pages 717-729.
Crossref
Crossref